Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Braess

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Haematologica|June 13, 2012
RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genesPhilipp A Greif, Nikola P Konstandin, Klaus H Metzeler, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Scientific Reports|July 28, 2018
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemiaRoman Hornung, Vindi Jurinovic, Aarif M N Batcha, et al.
Blood Advances|October 20, 2018
Genetic heterogeneity of cytogenetically normal AML with mutations of <i>CEBPA</i>Nikola P Konstandin, Friederike Pastore, Tobias Herold, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemiaKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
British Journal of Haematology|July 17, 2023
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcomeFriederike Pastore, Hanna Gittinger, Susanne Raab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysisMatthias Stelljes, Utz Krug, Dietrich W Beelen, et al.
European Journal of Haematology|November 9, 2017
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclinesEva Lengfelder, Dennis Görlich, Daniel Nowak, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Haematologica|June 13, 2012
RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genesPhilipp A Greif, Nikola P Konstandin, Klaus H Metzeler, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Scientific Reports|July 28, 2018
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemiaRoman Hornung, Vindi Jurinovic, Aarif M N Batcha, et al.
Blood Advances|October 20, 2018
Genetic heterogeneity of cytogenetically normal AML with mutations of <i>CEBPA</i>Nikola P Konstandin, Friederike Pastore, Tobias Herold, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemiaKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
British Journal of Haematology|July 17, 2023
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcomeFriederike Pastore, Hanna Gittinger, Susanne Raab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysisMatthias Stelljes, Utz Krug, Dietrich W Beelen, et al.
European Journal of Haematology|November 9, 2017
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclinesEva Lengfelder, Dennis Görlich, Daniel Nowak, et al.
Pageof 9